ArticleTherapeutic advances in drug safety2026
Incidence, risk factors, and prediction model of piperacillin/tazobactam-associated hypokalemia in neonates.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction and external validation of an early warning model for piperacillin/tazobactam-associated hypokalemia in critically ill patients.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Maintaining optimal potassium levels is critical in neonates. Piperacillin/tazobactam (TZP) is associated with hypokalemia in adults, but neonatal data are limited. Objectives: This study aimed to investigate the incidence, severity, and determinants of TZP-associated hypokalemia (TAH) in neonates and develop a predictive model for early detection. Design: Retrospective cohort study. Methods: Neonates treated with TZP between January 2019 and December 2024 at Xiamen Women and Children's Hospital were included. Demographic, laboratory, and medication data were extracted. Naranjo probability scores assessed TAH causality. Multivariate logistic regression identified predictors, and a nomogram predicted TAH occurrence. Nomogram performance was evaluated. Results: Among 1027 neonates initially screened, 358 met the inclusion criteria and were ultimately included in the analysis. The incidence of TAH in this cohort was 20.4% (73/358). Independent predictors included higher baseline serum creatinine ( Conclusion: Higher baseline serum creatinine, dopamine use, and lower serum calcium are independent predictors of neonatal TAH. The nomogram offers a user-friendly tool for TAH prediction, facilitating early detection and management in clinical practice. This study supports early detection, diagnosis, and intervention for neonatal TAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.